The Cochrane Collaboration says there are more than 3,000 genes linked to the risk of cerebral vein and cyst infections, including three that can cause the condition.
But they are not all well understood.
The most common gene linked to cerebral vein infections is called cis-regulatory-transmission-transmitting factor 4, or CRT4.
People with this mutation tend to have more veins that are less dense, so they have less blood circulating in their veins, which increases their risk of having a thrombus, or clot.
People who carry this mutation have more risk of developing a blood clot, especially in people with a family history of heart disease.
Celtic vein The second most common genetic mutation linked to cerebrovascular disease is the mutation that causes the Celtic vein, which is an irregular and curved vein in the heart.
People without this mutation are more likely to have a blood vessel blockage, which means they have fewer veins and arteries that are more vulnerable to clotting.
People with the genetic mutation are also more likely than other people to have cerebral vein cysts and a throned condition known as ciliac vein throrax, which causes swelling in the left heart muscle.
People in this group are more prone to developing cerebral vein disease.
In one case study, people with the Celtic variant of the gene had a 21 per cent increased risk of being diagnosed with coronary artery disease and had a 20 per cent higher risk of dying of cerebral venous thromboembolism.
Other cases of cerebral veins were seen in people who carry a gene called trans-regressive-transcriptional enhancer-interacting protein-1 (TWEBP-1), which can affect gene expression.
The Cochlearthon study has identified TWEBP, which has previously been associated with rare diseases such as cystic Fibrosis and cytopathic disorders.
This gene is also known to affect the ability to manufacture blood clotting factors, so it is a likely candidate for other genetic variants.
Celtics blood The third genetic variant linked to stroke is called cerebral veins thrombolastasis, or CVT.
People carrying this mutation often have an increased risk for stroke and may also have a higher incidence of the disease, particularly in people of European descent.
The most common risk factor for CVT is a family member with the CVS gene.
People of European ancestry have about a three-fold increased risk, and African-Americans have about seven times that.
CVT can lead to a condition called cerebral venosis, a condition in which blood clots form in the veins of the heart muscle, and stroke can also occur.
CVTs are most common in people over 70, but it is not always clear how the gene affects risk.
Researchers say it is unlikely that genetic factors are the main cause of stroke in this population, but they say this could be because CVTs and other risk factors can be passed down from father to son.
The most recent Cochlearthuron study analysed CVT variants associated with cerebral venoses.
They found that individuals with the most common CVT variant, known as the TWEB, had a 30 per cent increase in risk of stroke compared to people without CVT, a 10 per cent risk increase and no significant change in the risk for other CVT alleles.
Researchers say this is not enough to explain CVT and that there is also evidence that the risk could be caused by genetic factors.
People who carry the gene TWEF2 or TWEFP2 have a 20 to 30 per to 40 per cent greater risk of CVT compared to those who do not.
They also have higher levels of platelet aggregation in the arteries and thrombi in the circulatory system, which suggests a higher risk for cardiovascular events.
There are also some studies which show CVT patients have more problems than CVT controls, including poorer quality of life and increased risk factors for vascular disease, such as high blood pressure, diabetes and high cholesterol.
Chronic fatigue syndrome Chronic fatigue syndrome (CFS) is a condition where symptoms are severe enough to cause physical or mental impairment, but the condition is often difficult to diagnose or treat.
More than one in five people with CFS have the CNV gene variant, and there is some evidence that it may play a role in the disease.
Two studies in the Lancet Neurology journal showed that people with this variant were more likely and more severe than those without the gene to have problems with cognitive function, mood, concentration and overall well-being.
However, these studies were carried out in people living in rural areas, where the risk is higher.
Dr David Wilcox, a cardiologist and director of the Institute for Neuroscience and Medical Research at the University of Edinburgh